Summit Therapeutics Inc. announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented… read more.
Rates of obesity-linked cancers in China rose at an alarming 3.6% every year between 2007 and 2021 while non-obesity-related cancers remained stable, according to new data published in… read more.
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved Balversa (erdafitinib) as a once-daily oral monotherapy for the treatment of adult… read more.
Just 28% of U.S. women are aware that a healthful diet can lower the risk of developing breast cancer, according to a just-released Physicians Committee for Responsible Medicine/Morning… read more.
Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Ordspono (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse… read more.
Cervical cancer, the fourth most common cancer type in women, causes approximately 350,000 deaths each year, mainly in middle- and low-income countries. Human papillomavirus (HPV) infection is known… read more.
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application to expand the indication for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed… read more.
A new drug application (NDA) has been submitted to the FDA seeking the approval of mitomycin for intravesical solution (UGN 102) for the treatment of patients with low-grade,… read more.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive… read more.
Data from nearly 6000 smokers with cancer show that it may be easier to predict who will stop smoking than was previously thought. It is often important to… read more.
The FDA has granted priority review to asciminib (Scemblix) for the treatment of patients with newly diagnosed Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase (CP-CML)…. read more.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a review of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessment… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
